Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme
Vancouver, British Columbia–January 26, 2026 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme.
The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturaly derived psilocybin capsules in a 5 mg dosage form. Final packaging, labeling, and batch release were completed in accordance with Optimi’s Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, folowing receipt of the required Australian import permits.
“This production run has been released and approved for import, alowing Optimi to continue supplying MDMA and psilocybin into Australia’s regulated healthcare system,” said Dane Stevens, Chief Executive Officer of Optimi Health. “Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD.”
Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5 6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 milion people. According to the Australian Institute of Health and Welfare, more than 1.3 milion Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.
Australian clinics, hospital networks, and programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org . For global inquiries outside of Australia, please contact the Company at sales@optimihealth.ca
About Optimi Health Corp. Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca Forward-Looking Statements .
